We read with interest the article by Schulte-Hermann et al. [1| reporting supravenous hyperpigmentation in association with CHOP chemotherapy. These authors conclude that although pigmentary changes secondary to chemotherapy are frequent, this particular venous pattern is uncommon, and they attributed it to either cyclo-phosphamide or doxorubicin. We have recently observed 2 patients with similar supravenous hyperpigmentation. The first patient was a 7-year-old black male who underwent a bone marrow transplantation for acute lymphocytic leukemia after a course of polychemotherapy which included methotrexate, Ara-C, L-asparaginase, daunorubicin and 6-mercaptopurine. His pretransplantation conditioning consisted of total body irradiation, prednisone, cyclosporine, Ara-C and cyclo-phosphamide. All drugs were administered through a central line. One month after bone marrow transplantation, he developed a striking linear hyperpigmentation reproducing the superficial venous plexus of the anterior trunk ( fig. 1 ). There was also banded hyperpigmentation of the nails. The second patient was a 15-year-old black male with stage ΠIA nodular sclerosing Hodgkin disease treated with extended mantel radiation and combination chemotherapy with doxorubicin, bleomycin, vinblastine and dacarbazine. Six months after starting the monthly chemotherapeutic regimen he developed linear hyperpigmentation reproducing the venous channels of the right anterior forearm. There was no history of extravasation or phlebitis preceding the hyperpigmentation ( fig.  2) . Chemotherapy-induced hyperpigmentation is more frequent and prominent in dark-skinned individuals, and both our patients were African-American. It is difficult to know which drug is responsible for the observed hyperpigmentation. In our first patient, methotrexate, daunorubicin and cyclophosphamide may be implicated as all three are known to induce hyperpigmentation [2, 3]. However, the last doses of methotrexate and daunorubicin were administered more than 1 month before the pigmentary changes developed. In the second patient, the more plausible culprit drugs are bleomycin and doxorubicin. The venous pattern of pigmentation in this patient was distinct from the bleomycin-associated linear, flagellate hyperpigmentation in areas of excoriation and scratching [4].
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